-
公开(公告)号:US10906919B2
公开(公告)日:2021-02-02
申请号:US16220847
申请日:2018-12-14
申请人: UCB Biopharma SRL , Sanofi
发明人: Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号: C07D519/00 , C07F7/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18
摘要: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号:US11912721B2
公开(公告)日:2024-02-27
申请号:US17102790
申请日:2020-11-24
申请人: UCB Biopharma SRL , Sanofi
发明人: Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm MacCoss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号: C07D519/00 , C07D491/08 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18 , C07F7/18 , A61K31/4184 , A61K31/506 , A61K31/55
CPC分类号: C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804
摘要: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号:US20210155637A1
公开(公告)日:2021-05-27
申请号:US17102790
申请日:2020-11-24
申请人: UCB Biopharma SRL , Sanofi
发明人: Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号: C07D519/00 , C07F7/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18
摘要: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号:US10202405B2
公开(公告)日:2019-02-12
申请号:US15513357
申请日:2015-10-02
申请人: UCB Biopharma SPRL , Sanofi
发明人: Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号: C07D519/00 , C07F7/18 , C07D471/18 , C07D487/18 , C07D493/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D495/18 , C07D513/18
摘要: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号:US20170305932A1
公开(公告)日:2017-10-26
申请号:US15513357
申请日:2015-10-02
申请人: UCB Biopharma SPRL , Sanofi
发明人: Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号: C07D519/00 , C07D495/18 , C07D487/18 , C07D491/18 , C07F7/18 , C07D513/18
CPC分类号: C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804
摘要: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
-
-
-